secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0000078003-23-000111
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer Q3 revenue $13.2B (-42% YoY), adjusted LPS $(0.17) on $5.6B write-off; reaffirms FY guidance
--------------------------------------------------------------------------------

- Q3 revenues $13.2B, down 41% operationally; non-COVID products grew 10% operationally.
- Reported diluted LPS $(0.42); adjusted diluted LPS $(0.17), including $5.6B non-cash inventory write-offs.
- Reaffirms FY2023 guidance: revenue $58-61B, adjusted EPS $1.45-$1.65; expects $1B cost savings in 2023.
- Comirnaty revenue down 70% operationally; Paxlovid down 97% operationally; Abrysvo contributed $375M.
- Launched enterprise cost realignment program targeting at least $3.5B annual net savings by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800323000111/0000078003-23-000111-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800323000111/pfe-20231031.htm
  HTML page:      https://secwatch.observer/filing/0000078003-23-000111

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer